Showing results (191-200 of 216) with videos related to

Sort By:
Pageof 22
The New England Journal of Medicine|June 20, 2024
A Novel Anti-CD38 Monoclonal Antibody for Treating Immune ThrombocytopeniaYunfei Chen, Yanmei Xu, Huiyuan Li, et al.
Nature Communications|July 20, 2023
Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1Yuchen Gao, Ying Chi, Yunfei Chen, et al.
Signal Transduction and Targeted Therapy|April 23, 2024
Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trialYunfei Chen, Yanmei Xu, Ying Chi, et al.
Platelets|January 3, 2023
Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics studyXiaofan Liu, Yusheng Bai, Tao Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 21, 2025
Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia DevelopmentJingyuan Tong, Di Wang, Haoze Song, et al.
American Journal of Hematology|April 6, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 TrialNichola Cooper, Catherine M Broome, Yoshitaka Miyakawa, et al.
Therapeutic Advances in Hematology|May 8, 2026
Marstacimab for People with Severe Hemophilia A or Moderate to Severe Hemophilia B Without Inhibitors: A Plain Language Summary of Publication of the BASIS StudyDavide Matino, Andrew Palladino, Carrie Turich Taylor, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 9, 2024
Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in ChinaYuan Xu, Ying Wang, Runhui Wu, et al.
The Lancet. Haematology|April 7, 2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 studyXiaofan Liu, Hu Zhou, Yu Hu, et al.
BMJ (Clinical Research Ed.)|October 21, 2025
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trialYunfei Chen, Yanmei Xu, Jiawen Dai, et al.
Pageof 22